Contemporary Review of Peyronie's Disease Treatment

Curr Urol Rep. 2018 May 17;19(7):51. doi: 10.1007/s11934-018-0800-5.


Purpose: To analyze the literature on the current treatment options for Peyronie's disease (PD).

Recent findings: Intracavernosal injection therapy using collagenase clostridium histolyticum (CCH) has been widely adopted since its FDA approval in 2013. Based on the current evidence, it appears to be moderately efficacious for men with mild curvatures. Although a recent study has shown similar outcomes using a modified protocol requiring fewer injections, CCH remains an expensive medication. Surgery provides the most definitive treatment. The most common adverse effect following surgery is perceived loss of length. Length restoration procedures have recently been developed to address this with promising results reported in small series. There are a variety of medical treatment options for PD, with CCH getting the most attention for being the first drug to be FDA approved for PD treatment. It is the authors' opinion that the non-surgical therapy most likely to provide meaningful results is combination therapy utilizing oral, intralesional, and external traction therapy. Surgery remains the gold standard for definitive treatment.

Keywords: Andrology; Infertility; Intracavernosal injection therapy; Peyronie’s disease; Treatment.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Humans
  • Injections, Intralesional
  • Male
  • Microbial Collagenase / therapeutic use
  • Penile Induration / diagnosis
  • Penile Induration / etiology
  • Penile Induration / therapy*
  • Traction


  • Microbial Collagenase